Novogene(SH:688315)2022-10-24 16:00Financial Performance - Revenue for Q3 2022 reached ¥515,103,215.31, an increase of 8.61% year-over-year[8] - Net profit attributable to shareholders was ¥56,142,907.27, up 18.25% compared to the same period last year[8] - Net profit excluding non-recurring gains and losses increased by 43.90% to ¥57,433,960.16 in Q3 2022[8] - Basic earnings per share for Q3 2022 was ¥0.14, a decrease of 17.65% year-to-date[12] - Total operating revenue for the first three quarters of 2022 reached ¥1,364,823,824.09, an increase of 6.93% compared to ¥1,275,995,770.26 in the same period of 2021[33] - Net profit for the third quarter of 2022 was ¥115,306,030.16, a decrease of 12.04% from ¥131,029,348.76 in the same quarter of 2021[36] - Earnings per share for the third quarter of 2022 were ¥0.28, down from ¥0.34 in the same quarter of 2021[41] - Other comprehensive income after tax for the third quarter of 2022 was ¥15,829,461.82, compared to -¥5,473,124.39 in the same quarter of 2021[39] Assets and Liabilities - Total assets at the end of Q3 2022 amounted to ¥2,907,610,117.99, reflecting a 1.69% increase from the end of the previous year[12] - The company's total liabilities amounted to ¥991,630,752.17, a decrease from ¥1,061,852,902.16 in the previous year[33] - Total liabilities decreased to CNY 585,684,353.65 in Q3 2022 from CNY 654,114,652.91 in Q3 2021, a reduction of approximately 10.5%[57] - The total assets of the company reached ¥2,907,610,117.99, an increase from ¥2,859,351,915.80 in the previous year[33] - The total cash and cash equivalents at the end of the period were 11,400,109.94 RMB, down from 18,554,214.61 RMB in the previous year, reflecting a decrease of 38.5%[66] Cash Flow - Cash flow from operating activities for the year-to-date was ¥61,347,057.32, attributed to increased customer payments and VAT refunds[15] - The net cash flow from operating activities for the first three quarters of 2022 was ¥61,347,057.32, a significant improvement compared to a net outflow of ¥42,937,286.65 in the same period of 2021[43] - Cash inflow from operating activities totaled ¥1,455,840,121.68, up from ¥1,176,218,057.77 in the previous year, representing an increase of approximately 23.7%[43] - The total cash outflow from operating activities was ¥1,394,493,064.36, compared to ¥1,219,155,344.42 in 2021, indicating a rise of about 14.4%[43] - The net cash flow from financing activities was -¥40,300,244.68, a decline from a positive cash flow of ¥404,601,483.16 in the same period of 2021[47] Research and Development - R&D investment for Q3 2022 was ¥39,476,673.48, a decrease of 12.05% year-over-year[12] - R&D expenditure accounted for 7.66% of revenue, down 1.85 percentage points from the previous year[12] - Research and development expenses for the first three quarters of 2022 were ¥87,826,057.16, compared to ¥95,349,213.00 in the same period of 2021, indicating a decrease of 7.93%[36] - Research and development expenses for the first three quarters of 2022 amounted to CNY 52,809,206.07, down 29.1% from CNY 74,431,940.12 in the same period of 2021[57] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 4,976[18] - There were no significant changes in the top ten shareholders or their holdings during the reporting period[24] - The total equity attributable to shareholders increased to ¥1,907,437,664.01 from ¥1,791,810,149.25, representing a growth of 6.47%[33] - The company's total equity increased to CNY 1,686,224,176.68 in Q3 2022 from CNY 1,654,836,428.74 in Q3 2021, representing a growth of about 1.9%[56] Future Outlook - The company has not disclosed any significant new product developments or market expansions during the reporting period[25] - The company plans to focus on market expansion and new product development in the upcoming quarters to drive growth[60]